Pfizer Inc. shares fell 2% Tuesday despite the drugmaker topping Wall Street’s revenue and profit estimates in its ...

Pfizer's adjusted EPS of $0.63 surpassed the expected $0.47. Revenue reached $17.8 billion, exceeding the anticipated $17.35 ...

Pfizer faces stagnant revenue and patent cliffs. Learn why I downgraded PFE stock to Strong Sell despite a 24.7% YoY growth ...

Pfizer's Q4 2024 earnings beat expectations, but concerns over 2025 guidance and patent expirations led to stock decline. See ...

Pfizer (PFE) stock is up today after the pharmaceutical company reported earnings for the fourth quarter of 2024. The company ...

Pfizer Inc (PFE) reports robust financial performance with significant revenue growth and strategic progress in oncology and ...

Pfizer's fourth quarter beat expectations on strong sales of its Covid vaccine and pill, bolstering its sales as it seeks to ...

Pfizer ( PFE) reported fourth quarter and full-year 2024 earnings results Tuesday, narrowly beating Wall Street expectations ...

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) reported financial results for fourth-quarter and full-year 2024 and reaffirmed its 2025 financial guidance (5) provided on December 17, 2024. The ...

Pfizer Inc. shares fell 2% Tuesday despite the drugmaker topping Wall Street’s revenue and profit estimates in its fourth-quarter results. Analyst firm Edward Jones expects Pfizer’s future ...

Pharmaceuticals giant Pfizer (NYSE:PFE) reported fourth-quarter and full-year 2024 earnings on Tuesday, Feb. 4, that topped analysts' consensus estimates. The company reported an adjusted earnings ...